460 related articles for article (PubMed ID: 23838347)
21. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
[TBL] [Abstract][Full Text] [Related]
22. Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3.
Argiropoulos B; Yung E; Xiang P; Lo CY; Kuchenbauer F; Palmqvist L; Reindl C; Heuser M; Sekulovic S; Rosten P; Muranyi A; Goh SL; Featherstone M; Humphries RK
Blood; 2010 May; 115(20):4071-82. PubMed ID: 20237320
[TBL] [Abstract][Full Text] [Related]
23. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
Placke T; Faber K; Nonami A; Putwain SL; Salih HR; Heidel FH; Krämer A; Root DE; Barbie DA; Krivtsov AV; Armstrong SA; Hahn WC; Huntly BJ; Sykes SM; Milsom MD; Scholl C; Fröhling S
Blood; 2014 Jul; 124(1):13-23. PubMed ID: 24764564
[TBL] [Abstract][Full Text] [Related]
24. Differential requirement for wild-type Flt3 in leukemia initiation among mouse models of human leukemia.
Kamezaki K; Luchsinger LL; Snoeck HW
Exp Hematol; 2014 Mar; 42(3):192-203.e1. PubMed ID: 24269847
[TBL] [Abstract][Full Text] [Related]
25. MLL-TET1 fusion protein promotes immortalization of myeloid progenitor cells and leukemia development.
Kim HS; Oh SH; Kim JH; Kim JY; Kim DH; Lee SJ; Choi SU; Park KM; Ryoo ZY; Park TS; Lee S
Haematologica; 2017 Nov; 102(11):e434-e437. PubMed ID: 28798069
[No Abstract] [Full Text] [Related]
26. Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C.
Schwieger M; Schüler A; Forster M; Engelmann A; Arnold MA; Delwel R; Valk PJ; Löhler J; Slany RK; Olson EN; Stocking C
Blood; 2009 Sep; 114(12):2476-88. PubMed ID: 19584403
[TBL] [Abstract][Full Text] [Related]
27. PLZF mutation alters mouse hematopoietic stem cell function and cell cycle progression.
Vincent-Fabert C; Platet N; Vandevelde A; Poplineau M; Koubi M; Finetti P; Tiberi G; Imbert AM; Bertucci F; Duprez E
Blood; 2016 Apr; 127(15):1881-5. PubMed ID: 26941402
[TBL] [Abstract][Full Text] [Related]
28. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis.
Ono R; Nakajima H; Ozaki K; Kumagai H; Kawashima T; Taki T; Kitamura T; Hayashi Y; Nosaka T
J Clin Invest; 2005 Apr; 115(4):919-29. PubMed ID: 15761502
[TBL] [Abstract][Full Text] [Related]
29. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
30. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells.
Hess JL; Bittner CB; Zeisig DT; Bach C; Fuchs U; Borkhardt A; Frampton J; Slany RK
Blood; 2006 Jul; 108(1):297-304. PubMed ID: 16507773
[TBL] [Abstract][Full Text] [Related]
31. Initiation of MLL-rearranged AML is dependent on C/EBPα.
Ohlsson E; Hasemann MS; Willer A; Lauridsen FK; Rapin N; Jendholm J; Porse BT
J Exp Med; 2014 Jan; 211(1):5-13. PubMed ID: 24367003
[TBL] [Abstract][Full Text] [Related]
32. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
[TBL] [Abstract][Full Text] [Related]
33. [The mechanism of MLL-rearranged leukemogenesis and its targeted therapies].
Yokoyama A
Rinsho Ketsueki; 2021; 62(8):988-997. PubMed ID: 34497239
[TBL] [Abstract][Full Text] [Related]
34. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells.
Zheng X; Beissert T; Kukoc-Zivojnov N; Puccetti E; Altschmied J; Strolz C; Boehrer S; Gul H; Schneider O; Ottmann OG; Hoelzer D; Henschler R; Ruthardt M
Blood; 2004 May; 103(9):3535-43. PubMed ID: 14739224
[TBL] [Abstract][Full Text] [Related]
35. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
36. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
[TBL] [Abstract][Full Text] [Related]
37. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9.
So CW; Karsunky H; Wong P; Weissman IL; Cleary ML
Blood; 2004 Apr; 103(8):3192-9. PubMed ID: 15070702
[TBL] [Abstract][Full Text] [Related]
38. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression.
Wong P; Iwasaki M; Somervaille TC; Ficara F; Carico C; Arnold C; Chen CZ; Cleary ML
Cancer Res; 2010 May; 70(9):3833-42. PubMed ID: 20406979
[TBL] [Abstract][Full Text] [Related]
39. Acute myeloid leukemia induced by MLL-ENL is cured by oncogene ablation despite acquisition of complex genetic abnormalities.
Horton SJ; Walf-Vorderwülbecke V; Chatters SJ; Sebire NJ; de Boer J; Williams O
Blood; 2009 May; 113(20):4922-9. PubMed ID: 19029444
[TBL] [Abstract][Full Text] [Related]
40. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.
Zeisig BB; Milne T; García-Cuéllar MP; Schreiner S; Martin ME; Fuchs U; Borkhardt A; Chanda SK; Walker J; Soden R; Hess JL; Slany RK
Mol Cell Biol; 2004 Jan; 24(2):617-28. PubMed ID: 14701735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
